ArticleBMC microbiology2026
Comprehensive analysis of microorganisms in severe septic patients in the intensive care unit by mNGS and microbial culture.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Next-generation sequencing in the etiological diagnosis of severe childhood pneumonia.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSevere sepsis is a life-threatening condition involving dysregulated systemic inflammatory responses and acute organ dysfunctions. Timely and accurate pathogen identification is critical for the effective treatment of severe septic patients in the intensive care unit (ICU). Although metagenomic next-generation sequencing (mNGS) enables the sensitive and unbiased detection of pathogens, its clinical implications in identification of causative pathogens, the association with the outcomes and the development of treatment regimens in such patients remain underexplored.
methods184 clinical samples were collected from 81 severe septic patients and subjected to mNGS analysis. Blood and bronchoalveolar lavage fluid (BAL) samples were collected from the majority of patients, while sputum, cerebrospinal fluid (CSF), pleural effusion (PE), ascites, urine, hydropericardium (HPC) and blister effusion (BE) samples were also collected from select patients. Microorganisms were detected by DNA and RNA mNGS and the top 5 microorganisms detected by mNGS in each sample were used for analysis. Microbes were isolated from most patients and the isolates were tested for drug susceptibility.
resultsmNGS identified 183 top 5 microorganisms, with bacteria (92.3%), viruses (3.3%) and fungi (2.7%) as the major detected microbes. Among them, 40, 98 and 45 were pathogenic (21.9%), opportunistic (53.6%) and non-pathogenic (24.6%), respectively. Significantly more pathogenic microbes were detected in the sputum (83.3%) and the bronchoalveolar lavage fluid (BAL; 75.0%) than the blood (36.1%) by RNA mNGS (87.4%) than DNA mNGS (58.2%). Patients having the top-1 pathogenic microorganism detected by DNA mNGS or 4-5 pathogenic microorganisms detected by RNA mNGS had a poor association with clinical outcomes. Moreover, detection of R. pickettii, C. difficile and S. enterica were significantly associated with high mortality. The majority of patients (89.5%) were positive for microbial cultures. Each of these patients had at least one drug-resistant organism and nearly half (45.1%) were infected with two or more drug-resistant strains.
conclusionsDetection of predominant pathogenic microorganisms or particular bacteria in the sputum or BAL samples by mNGS are associated with poor clinical outcomes among severe septic patients in ICU in this cohort. The high prevalence of multidrug-resistant bacteria among these patients underscores the importance of integration of mNGS with antimicrobial susceptibility assessment in the clinical practice to develop the most effective treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.